Sandbox Reserved 1110

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (15:05, 17 January 2020) (edit) (undo)
 
(9 intermediate revisions not shown.)
Line 3: Line 3:
-
== 5LSD==
+
 
 +
==5LSD==
<StructureSection load='5LSD' size='350' side='right' caption='Mouse recombinant Nerve Growth Factor (PDB entry [[5LSD]])' scene=''>
<StructureSection load='5LSD' size='350' side='right' caption='Mouse recombinant Nerve Growth Factor (PDB entry [[5LSD]])' scene=''>
 +
 +
==General informations==
Total Structure Weight: '''26554.02 Da'''
Total Structure Weight: '''26554.02 Da'''
Line 12: Line 15:
Residue Count: '''236'''
Residue Count: '''236'''
-
5LSD is the recombinant mouse '''Nerve Growth Factor (NGF)''', that does not bind to '''any ligand'''. Therefore it allows conclusions on the features of its binding loops. Through 5LSD, 3 questions can be targeted: (i) how is the NGF N-terminus structured in the absence of ligands? (ii) how flexible/rigid are the loops and how does their dynamics may reflect on the overall structural plasticity of mature NGF? (iii) how much do the loops contribute to antibody recognition?<ref>PMID: 28083536</ref>
+
5LSD is the recombinant mouse '''Nerve Growth Factor (NGF)''', that does not bind to '''any ligand'''. Therefore it allows conclusions on the features of its binding loops, i.e. the NGF N-Terminus structure in absence of ligands. Further, the flexibility of the loops can be targeted through 5LSD as well as their impact on the overall structural plasticity of mature NGF. 5LSD also clarifies about the loops´ contribution to antibody recognition. <ref>PMID: 28083536</ref>
-
 
+
== Structure ==
== Structure ==
-
Since the X-ray crystal structure of NGF has been known since the ‘90s, the general structure of 5LSD can be described by relatable structures such as a '''β-sandwich fold''', with '''four loop regions''' (I,II,III and V) which are the center of interactions with ligands but which are inactive in the case of 5LSD.
+
Since the X-ray crystal structure of NGF has been known since the ‘90s, the general structure of 5LSD can be described by relatable structures such as a <scene name='82/829363/Feuillets_beta/1'>β-sandwich fold</scene>, with '''four loop regions''' (<scene name='82/829363/Loop_i2/1'>I</scene>,<scene name='82/829363/Loops_ii/1'>II</scene>,<scene name='82/829363/Loops_iii/1'>III</scene> and <scene name='82/829363/Loops_v/1'>V</scene>) which are the center of interactions with ligands but which are inactive in the case of 5LSD.
-
 
+
-
In this PDB representation, there are two 118 amino acids chains, <scene name='82/829363/Chain_a/3'>chain A</scene> and chain B, which are similar to the residues NGF ones, except for these fragments, proper to 5LSD. [https://www.ncbi.nlm.nih.gov/Structure/pdb/5LSD]
+
-
In the absence of partners, the NGF N-terminus has a strong tendency to fold into a '''helix'''. This challenges the current view that this region is unstructured. Experiments have shown that this N-terminus plays an important role in many processes, and its absence triggers a loss of affinity with the receptor '''TrkA'''. The loops, especially II and V, and the C-terminus are relatively more flexible than the more rigid β-sheet regions (showing hetNOE values lower than the average of 0.7). However, the loop variations are relatively small compared to the flexibility of the N- and C-termini, which indicates that the loops are plastic but not flexible. <ref>PMID: 28083536</ref>
+
In this PDB representation, there are two 118 amino acids chains, <scene name='82/829363/Chain_a/3'>chain A</scene> and <scene name='82/829363/Chain_b/1'>chain B</scene>, which are similar to the residues NGF ones, except for <scene name='82/829363/No_ngf/1'>these fragments</scene>, proper to 5LSD. [https://www.ncbi.nlm.nih.gov/Structure/pdb/5LSD]
 +
In the absence of partners, the NGF N-terminus has a strong tendency to fold into a <scene name='82/829363/Helix_n-terminus/1'>helix</scene>. This challenges the current view that this region is unstructured. Experiments have shown that this N-terminus plays an important role in many processes, and its absence triggers a loss of affinity with the receptor '''TrkA'''. The loops, especially II and V, and the C-terminus are relatively more flexible than the more rigid β-sheet regions (showing hetNOE values lower than the average of 0.7). However, the loop variations are relatively small compared to the flexibility of the N- and C-termini, which indicates that the loops are plastic but not flexible. <ref>PMID: 28083536</ref>
== The neurotrophin family ==
== The neurotrophin family ==
Line 28: Line 30:
The members of the neurotrophin family are then as useful in prenatal organisms for the development of cortexes and in adulthood, where they control synaptic function and plasticity and sustain neuronal cell survival.
The members of the neurotrophin family are then as useful in prenatal organisms for the development of cortexes and in adulthood, where they control synaptic function and plasticity and sustain neuronal cell survival.
-
== Disease and use in Biotechnologies/ Relevance ==
+
== Diseases and use in Biotechnologies/ Relevance ==
As NGF is the prototype of the neurotrophin family, a better understanding of NGF could lead to a better understanding of the whole family. A better knowledge of NGF, i.e. through 5LSD, is supportive.
As NGF is the prototype of the neurotrophin family, a better understanding of NGF could lead to a better understanding of the whole family. A better knowledge of NGF, i.e. through 5LSD, is supportive.
Line 37: Line 39:
The NMR structure of 5LSD lead to the conclusion that NGF has long plastic but relatively rigid loops, which is of crucial importance for future drug design.<ref>PMID: 24691709</ref>
The NMR structure of 5LSD lead to the conclusion that NGF has long plastic but relatively rigid loops, which is of crucial importance for future drug design.<ref>PMID: 24691709</ref>
 +
</StructureSection>
== References ==
== References ==
<references/>
<references/>

Current revision

This Sandbox is Reserved from 25/11/2019, through 30/9/2020 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1091 through Sandbox Reserved 1115.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing



5LSD

Mouse recombinant Nerve Growth Factor (PDB entry 5LSD)

Drag the structure with the mouse to rotate

References

  1. Paoletti F, de Chiara C, Kelly G, Covaceuszach S, Malerba F, Yan R, Lamba D, Cattaneo A, Pastore A. Conformational Rigidity within Plasticity Promotes Differential Target Recognition of Nerve Growth Factor. Front Mol Biosci. 2016 Dec 26;3:83. doi: 10.3389/fmolb.2016.00083. eCollection, 2016. PMID:28083536 doi:http://dx.doi.org/10.3389/fmolb.2016.00083
  2. Paoletti F, de Chiara C, Kelly G, Covaceuszach S, Malerba F, Yan R, Lamba D, Cattaneo A, Pastore A. Conformational Rigidity within Plasticity Promotes Differential Target Recognition of Nerve Growth Factor. Front Mol Biosci. 2016 Dec 26;3:83. doi: 10.3389/fmolb.2016.00083. eCollection, 2016. PMID:28083536 doi:http://dx.doi.org/10.3389/fmolb.2016.00083
  3. Tiveron C, Fasulo L, Capsoni S, Malerba F, Marinelli S, Paoletti F, Piccinin S, Scardigli R, Amato G, Brandi R, Capelli P, D'Aguanno S, Florenzano F, La Regina F, Lecci A, Manca A, Meli G, Pistillo L, Berretta N, Nistico R, Pavone F, Cattaneo A. ProNGF\NGF imbalance triggers learning and memory deficits, neurodegeneration and spontaneous epileptic-like discharges in transgenic mice. Cell Death Differ. 2013 Aug;20(8):1017-30. doi: 10.1038/cdd.2013.22. Epub 2013, Mar 29. PMID:23538417 doi:http://dx.doi.org/10.1038/cdd.2013.22
  4. Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs. 2014 Apr;74(6):619-26. doi: 10.1007/s40265-014-0208-6. PMID:24691709 doi:http://dx.doi.org/10.1007/s40265-014-0208-6
  5. Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs. 2014 Apr;74(6):619-26. doi: 10.1007/s40265-014-0208-6. PMID:24691709 doi:http://dx.doi.org/10.1007/s40265-014-0208-6
Personal tools